Bortezomib Retreatment in Relapsed Multiple Myeloma – Results from a Retrospective Multicentre Survey in Germany and Switzerland

Publisher： Karger

E-ISSN： 1423-0232|79|3-4|247-254

ISSN： 0030-2414

Source： Oncology, Vol.79, Iss.3-4, 2011-03, pp. : 247-254

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 100, Iss. 1, 2018-01 ,pp. : 10-19

John Wiley & Sons Inc

Access to resources Recommend Favorite

How to Treat Multiple Myeloma: Thoughts on a Multicentre Survey in Germany

By  

Oncology Research and Treatment, Vol. 33, Iss. 11, 2010-10 ,pp. : 577-578

Karger

Access to resources Recommend Favorite

Bortezomib in Relapsed Multiple Myeloma – Results of a Non-Interventional Study by Office-Based Haematologists

By  

Oncology Research and Treatment, Vol. 32, Iss. 4, 2009-03 ,pp. : 175-180

Karger

Access to resources Recommend Favorite

RAS mutation status and bortezomib therapy for relapsed multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 6, 2015-06 ,pp. : 905-908

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term outcomes for newly‐diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 3, 2015-11 ,pp. : 373-377

John Wiley & Sons Inc

Access to resources Recommend Favorite